Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 5

Augmentation treatment in major depressive disorder: focus on aripiprazole

Authors J Craig Nelson, Andrei Pikalov, Robert M Berman

Published 10 October 2008 Volume 2008:4(5) Pages 937—948


Review by Single-blind

Peer reviewer comments 3

J Craig Nelson1, Andrei Pikalov2, Robert M Berman3

1University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USA

Abstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.

Keywords: major depression, antipsychotic, mood disorder, aripiprazole

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R

Neuropsychiatric Disease and Treatment 2011, 7:303-312

Published Date: 24 May 2011

Readers of this article also read:

Sustained-release nanoART formulation for the treatment of neuroAIDS

Jayant RD, Atluri VSR, Agudelo M, Sagar V, Kaushik A, Nair M

International Journal of Nanomedicine 2015, 10:1077-1093

Published Date: 4 February 2015

Analysis of SiO2 nanoparticles binding proteins in rat blood and brain homogenate

Shim KH, Hulme J, Maeng EH, Kim MK, An SSA

International Journal of Nanomedicine 2014, 9:207-215

Published Date: 15 December 2014

Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study

Babu KG, Prabhash K, Vaid AK, Sirohi B, Diwakar RB, Rao R, Kar M, Malhotra H, Nag S, Goswami C, Raina V, Mohan R

OncoTargets and Therapy 2014, 7:1051-1060

Published Date: 13 June 2014

Catalytic nanomedicine technology: copper complexes loaded on titania nanomaterials as cytotoxic agents of cancer cell

Lopez T, Ortiz-Islas E, Guevara P, Gómez E

International Journal of Nanomedicine 2013, 8:581-592

Published Date: 9 February 2013

Coseeded Schwann cells myelinate neurites from differentiated neural stem cells in neurotrophin-3-loaded PLGA carriers

Xiong Y, Zhu JX, Fang ZY, Zeng CG, Zhang C, Qi GL, Li MH, Zhang W, Quan DP, Wan J

International Journal of Nanomedicine 2012, 7:1977-1989

Published Date: 16 April 2012

Central corneal thickness in black Cameroonian ocular hypertensive and glaucomatous subjects

Christelle Domngang Noche, André Omgbwa Eballe, Assumpta Lucienne Bella

Clinical Ophthalmology 2010, 4:1371-1377

Published Date: 24 November 2010

Update on ropinirole in the treatment of Parkinson’s disease

Holly A Shill, Mark Stacy

Neuropsychiatric Disease and Treatment 2009, 5:33-36

Published Date: 21 December 2008

Once-daily treatment of ADHD with guanfacine: patient implications

Brandon C Strange

Neuropsychiatric Disease and Treatment 2008, 4:499-506

Published Date: 6 June 2008